Suggested remit - To appraise the clinical and cost effectiveness of mexiletine within its marketing authorisation for treating myotonia in adults with non-dystrophic myotonic disorders.
Status In progress
Process STA 2018
ID number 1488

Provisional Schedule

Committee meeting: 1 05 August 2020
Expected publication 14 October 2020

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Lupin Healthcare (mexiletine)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Muscular Dystrophy UK
Professional groups Royal College of Physicians


Comparator companies GlaxoSmithKline UK
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
16 December 2019 Following a request from the company, Lupin Healthcare, to delay the submission we have agreed new timelines for this appraisal. As a consequence, the first committee meeting that was originally planned for 4 June 2020 has been rescheduled to 5 August 2020.
23 September 2019 Invitation to participate
23 September 2019 In progress, Invitation to Participate
23 January 2019 (10:00) Scoping workshop (London)
19 November 2018 - 17 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators: 1488

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance